BSE - Delayed Quote INR

Aurobindo Pharma Limited (AUROPHARMA.BO)

1,171.95

+39.15

+(3.46%)

At close: April 17 at 3:29:31 PM GMT+5:30

Aurobindo Pharma Ltd (BOM:524804) Q3 2025 Earnings Call Highlights: Record Revenue and ...

Aurobindo Pharma Ltd (BOM:524804) reports its highest ever quarterly revenue, driven by strong US and European sales, while navigating operational challenges and market pressures.

GuruFocus.com 2 months ago

AUROPHARMA.NS
Aurobindo Pharma Outperforms Expectations with Strong Q4, Eyes Robust Growth Ahead

Aurobindo Pharma (NS:ARBN) has outperformed expectations in the fourth quarter of FY24, with both sales and EBITDA showing significant year-over-year growth. Sales increased by 17%, while EBITDA surged by an impressive 68%, surpassing both Goldman Sachs (NYSE:GS)' projections and those of the broader market. The EBITDA margin also exceeded forecasts, reaching 22.3%, which is 101 basis points higher than Goldman Sachs' estimate.

Investing.com 10 months ago

AUROPHARMA.NS

Performance Overview

Return	AUROPHARMA.BO	S&P BSE SENSEX (^BSESN)
YTD	-12.17%	+0.53%
1-Year	+5.60%	+7.69%
3-Year	+74.77%	+34.65%